Bone Biologics Corp reports results for the quarter ended in June - Earnings Summary

Reuters08-10

* Bone Biologics Corp reported a quarterly adjusted loss of 67 cents per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $-3.84. The lone analyst forecast for the quarter was for a loss of $1.39 per share.

* Reported revenue was zero; analysts expected zero.

* Bone Biologics Corp's reported EPS for the quarter was a loss of 67 cents.

* The company reported a quarterly loss of $783 thousand.

* Bone Biologics Corp shares had risen by 30.3% this quarter and lost 64.8% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 81.5% in the last three months.

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

*

* Wall Street's median 12-month price target for Bone Biologics Corp is $19.50

This summary was machine generated from LSEG data August 9 at 10:14 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Jun. 30 2024 -1.39 -0.67 Beat

Mar. 31 2024 -7.60 -1.31 Beat

Dec. 31 2023 -5.60 -2.47 Beat

Sep. 30 2023 -24.32 -4.88 Beat

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2458406525?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-10 06:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2458406525","market":"us","top_or_hot":-1,"title":"Bone Biologics Corp reports results for the quarter ended in June - Earnings Summary","media":"Reuters","content":"<html><body><p>* <a href=\"https://laohu8.com/S/BBLG\">Bone Biologics Corp</a>    reported a quarterly adjusted loss of 67 cents per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $-3.84.  The lone analyst forecast for the quarter was for a loss of $1.39 per share. </p><p>   * Reported revenue was zero; analysts expected zero. </p><p>   * <a href=\"https://laohu8.com/S/BBLGD\">Bone Biologics Corp</a>'s reported EPS for the quarter was a loss of 67 cents.</p><p>   * The company reported a quarterly loss of $783 thousand.</p><p>   * Bone Biologics Corp shares had risen by 30.3% this quarter and lost 64.8% so far this year.</p><p>FORECAST CHANGES</p><p>   * The mean earnings estimate of analysts had risen by about 81.5% in the last three months. </p><p>   * In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.</p><p>RECOMMENDATIONS</p><p>   * </p><p>   * Wall Street's median 12-month price target for Bone Biologics Corp is $19.50 </p><p>This summary was machine generated from LSEG data August 9 at 10:14 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,</p><p>                                                MISSED</p><p>Jun. 30 2024      -1.39          -0.67          Beat</p><p>Mar. 31 2024      -7.60          -1.31          Beat</p><p>Dec. 31 2023      -5.60          -2.47          Beat</p><p>Sep. 30 2023      -24.32         -4.88          Beat</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bone Biologics Corp reports results for the quarter ended in June - Earnings Summary</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBone Biologics Corp reports results for the quarter ended in June - Earnings Summary\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-10 06:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>* Bone Biologics Corp    reported a quarterly adjusted loss of 67 cents per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $-3.84.  The...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BBLG","symbol_name":"Bone Biologics Corp","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2458406525","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2458406525","pubTimestamp":1723241745,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"* Bone Biologics Corp    reported a quarterly adjusted loss of 67 cents per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $-3.84.  The l","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BBLG":"Bone Biologics Corp"},"translate_title":"Bone Biologics Corp报告截至6月份的季度业绩-收益摘要","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBLG":0.9},"content_text":"* Bone Biologics Corp    reported a quarterly adjusted loss of 67 cents per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $-3.84.  The lone analyst forecast for the quarter was for a loss of $1.39 per share.    * Reported revenue was zero; analysts expected zero.    * Bone Biologics Corp's reported EPS for the quarter was a loss of 67 cents.   * The company reported a quarterly loss of $783 thousand.   * Bone Biologics Corp shares had risen by 30.3% this quarter and lost 64.8% so far this year.FORECAST CHANGES   * The mean earnings estimate of analysts had risen by about 81.5% in the last three months.    * In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.RECOMMENDATIONS   *    * Wall Street's median 12-month price target for Bone Biologics Corp is $19.50 This summary was machine generated from LSEG data August 9 at 10:14 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,                                                MISSEDJun. 30 2024      -1.39          -0.67          BeatMar. 31 2024      -7.60          -1.31          BeatDec. 31 2023      -5.60          -2.47          BeatSep. 30 2023      -24.32         -4.88          Beat","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2458406525"}